2-oxindole






90 Article(s)
Download
PMID
Title
Journal
Pub. Date
#Total Relationship(s)
1 1768136 Degradation of substituted indoles by an indole-degrading methanogenic consortium. Appl Environ Microbiol 1991 Sep 1
2 8558432 Metabolism of 3-methylindole by vaccinia-expressed P450 enzymes: correlation of 3-methyleneindolenine formation and protein-binding. J Pharmacol Exp Ther 1996 Jan 1
3 9260266 5-HT1A and 5-HT2A receptor affinity and functional profile of some N-[3-(4-aryl-1-piperazinyl)propyl] derivatives of indolin-2(1H)-one, quinolin-2(1 H)-one and isoquinolin-1(2H)-one. Part 30: Structure-activity relationship studies of CNS agents. Pharmazie 1997 Jun 2
4 9263136 Effects of tenidap and nonsteroidal antiinflammatory drugs on the response of cultured human T cells to interleukin 2 in rheumatoid arthritis. J Rheumatol 1997 Aug 1
5 9886767 Electrophysiological studies on oxindole, a neurodepressant tryptophan metabolite. Br J Pharmacol 1998 Dec 1
6 10652431 Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative. Int J Cancer 2000 Feb 1 2
7 11728181 Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis. J Med Chem 2001 Dec 6 4
8 11741481 Oxindole derivatives as orally active potent growth hormone secretagogues. J Med Chem 2001 Dec 20 3
9 12636425 Enantioselective fluorination mediated by N-fluoroammonium salts of cinchona alkaloids: first enantioselective synthesis of BMS-204352 (MaxiPost). J Org Chem 2003 Mar 21 1
10 12659774 Synthesis of potent oxindole CDK2 inhibitors. Bioorg Med Chem 2003 Apr 17 2
11 12943231 Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cell Mol Life Sci 2003 Jul 2
12 14741403 The involvement of VEGF receptors and MAPK in the cannabinoid potentiation of Ca2+ flux into N18TG2 neuroblastoma cells. Brain Res Mol Brain Res 2004 Jan 5 3
13 14870776 RET/PTC oncoproteins: molecular targets of new drugs. Tumori 2003 Sep-Oct 4
14 15012993 A new series of potent oxindole inhibitors of CDK2. Bioorg Med Chem Lett 2004 Feb 23 3
15 15013000 Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg Med Chem Lett 2004 Feb 23 1
16 15963493 Suppressive effects of isorhynchophylline on 5-HT2A receptor function in the brain: behavioural and electrophysiological studies. Eur J Pharmacol 2005 Jul 11 1
17 15978807 SAR studies of 6-aryl-1,3-dihydrobenzimidazol-2-ones as progesterone receptor antagonists. Bioorg Med Chem Lett 2005 Aug 1 3
18 16042502 Toxicological aspects of the South American herbs cat's claw (Uncaria tomentosa) and Maca (Lepidium meyenii) : a critical synopsis. Toxicol Rev 2005 1
19 16533152 Synthesis and pharmacological profile of an orally-active growth hormone secretagogue, SM-130686. Comb Chem High Throughput Screen 2006 Mar 1
20 16632252 Selective kinase inhibition by exploiting differential pathway sensitivity. Chem Biol 2006 Apr 1
21 16644221 Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers. Bioorg Med Chem Lett 2006 Jul 1 2
22 17266627 3D-QSAR CoMFA study on oxindole derivatives as cyclin dependent kinase 1 (CDK1) and cyclin dependent kinase 2 (CDK2) inhibitors. Med Chem 2007 Jan 8
23 17386461 Structure-activity relationship study of oxindole-based inhibitors of cyclin-dependent kinases based on least-squares support vector machines. Anal Chim Acta 2007 Jan 9 1
24 17761171 The oxindole/imidazole derivative C16 reduces in vivo brain PKR activation. FEBS Lett 2007 Sep 18 2
25 17911024 Potent oxindole based human beta3 adrenergic receptor agonists. Bioorg Med Chem Lett 2007 Nov 15 2
26 18307332 Fragment-based de novo ligand design by multiobjective evolutionary optimization. J Chem Inf Model 2008 Mar 2
27 18680359 Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. J Med Chem 2008 Aug 28 2
28 19518155 Enantioselective organocatalytic anti-Mannich-type reaction of N-unprotected 3-substituted 2-oxindoles with aromatic N-Ts-aldimines. J Org Chem 2009 Jun 19 2
29 20045315 Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. Bioorg Med Chem Lett 2010 Feb 1 2
30 20570526 Synthesis and structure-activity relationship of 6-arylureido-3-pyrrol-2-ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors. Bioorg Med Chem 2010 Jul 1 2
31 21028894 Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives. J Med Chem 2010 Nov 25 4
32 21316225 Oxindole derivatives as inhibitors of TAK1 kinase. Bioorg Med Chem Lett 2011 Mar 15 3
33 21426074 Ghrelin receptor modulators and their therapeutic potential. Future Med Chem 2009 Apr 1
34 21570288 Discovery of XEN907, a spirooxindole blocker of NaV1.7 for the treatment of pain. Bioorg Med Chem Lett 2011 Jun 15 1
35 22019188 Synthesis and biological evaluation of 2-indolinone derivatives as potential antitumor agents. Eur J Med Chem 2011 Dec 2
36 22070999 Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations. J Mol Graph Model 2012 Feb 1
37 22377517 Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists. Bioorg Med Chem Lett 2012 Apr 1 1
38 22832319 Synthesis and biological evaluation of novel oxindole derivatives for imaging neurofibrillary tangles in Alzheimer's disease. Bioorg Med Chem Lett 2012 Sep 1 1
39 23340601 Asymmetric direct α-alkylation of 2-oxindoles with Michler's hydrol catalyzed by bis-cinchona alkaloid-Brønsted acid via an SN1-type pathway. Chem Commun (Camb) 2013 Feb 25 1
40 23659209 Discovery of potent, selective chymase inhibitors via fragment linking strategies. J Med Chem 2013 Jun 13 1
41 24410404 Metal-free synthesis of 2-oxindoles via PhI(OAc)2-mediated oxidative C–C bond formation. J Org Chem 2014 Feb 7 2
42 24670223 (DHQ)2AQN-catalyzed asymmetric substitution of isatin-derived hydrazones with O-Boc-protected Morita-Baylis-Hillman adducts: A strategy for synthesizing enantioenriched azo compounds incorporating an oxindole scaffold. J Org Chem 2014 Apr 18 1
43 24949819 Development and validation of a LC-MS/MS method for assessment of an anti-inflammatory indolinone derivative by in vitro blood-brain barrier models. J Pharm Biomed Anal 2014 Sep 2
44 25043407 Direct asymmetric anti-Mannich-type reactions catalyzed by cinchona alkaloid derivatives. Chirality 2014 Dec 1
45 25705992 Enantiocontrolled synthesis of a tetracyclic aminal corresponding to the core subunit of diazonamide A. J Org Chem 2015 Mar 20 1
46 25776143 Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014). Expert Opin Ther Pat 2015 Jun 1
47 25808617 Computational analysis of spiro-oxindole inhibitors of the MDM2-p53 interaction: insights and selection of novel inhibitors. J Biomol Struct Dyn 2016 1
48 26340696 Highly chemoselective synthesis of dimeric 2-oxindoles with a C-3/C-5' linkage via Friedel-Crafts alkylations of 2-oxindoles with 3-hydroxy-2-oxindoles. Org Biomol Chem 2015 Nov 21 6
49 26416217 QSAR and molecular docking studies on oxindole derivatives as VEGFR-2 tyrosine kinase inhibitors. J Recept Signal Transduct Res 2016 3
50 26428872 Design, synthesis, and biological evaluation of oxindole derivatives as antidepressive agents. Bioorg Med Chem Lett 2015 Nov 15 1